Johnson & Johnson files for authorization for COVID-19 vaccine booster shot
Johnson & Johnson said an additional second vaccine that given two months after the first increased its effectiveness up to 94 percent This was compared with 70 percent protection with the single dose.
There are still some scientists questioning the need for booster shots due to many people in the United States and other countries remain unvaccinated.
The Biden administration announced the push for an extra dose in August to ramp up protection against the highly transmissible delta variant.
More than 15 million Americans have received Johnson & Johnson’s vaccine, which is administered as a single dose, according to the latest data from the Centers for Disease Control and Prevention.
The vaccine maker last month said an additional second shot of its vaccine given about two months after the first increased its effectiveness to 94 percent, compared with 70 percent protection with the single dose.
The government will not extend the shelf life of hundreds of thousands of unused Johnson & Johnson Covid vaccine doses.
AP news reports– “ The FDA is convening its outside panel of advisers next week to review booster data from both J&J and Moderna. It’s the first step in a review process that also includes sign-off from the leadership of both the FDA and the Centers for Disease Control and Prevention. If both agencies give the go-ahead, Americans could begin getting J&J and Moderna boosters later this month.”
After receiving the J&J/Janssen COVID-19 Vaccine, there is risk for a rare but serious adverse event—blood clots with low platelets (thrombosis with thrombocytopenia syndrome, or TTS). Women younger than 50 years old should especially be aware of their increased risk for this rare adverse event. Source: CDC.gov
Johnson & Johnson’s Janssen (J&J/Janssen) COVID-19 Vaccine: Women younger than 50 years old should especially be aware of the rare risk of blood clots with low platelets after vaccination. There are other COVID-19 vaccines available for which this risk has not been seen. If you received a J&J/Janssen COVID-19 Vaccine, here is what you need to know. Read the CDC/FDA statement.
Data Supporting Need for a Booster Shot
Studies show that after getting vaccinated against COVID-19, protection against the virus may decrease over time and be less able to protect against the Delta variant. Although COVID-19 vaccination for adults aged 65 years and older remains effective in preventing severe disease, recent data pdf icon[4.7 MB, 88 pages] suggest vaccination is less effective at preventing infection or milder illness with symptoms. Emerging evidence also shows that among healthcare and other frontline workers, vaccine effectiveness against COVID-19 infections is decreasing over time. This lower effectiveness is likely due to the combination of decreasing protection as time passes since getting vaccinated (e.g., waning immunity) as well as the greater infectiousness of the Delta variant.